Sadahiro Sotaro, Suzuki Toshiyuki, Ishikawa Kenji, Nakamura Tomoki, Tanaka Yoichi, Masuda Takahisa, Mukoyama Sayuri, Yasuda Seiei, Tajima Tomoo, Makuuchi Hiroyasu, Murayama Chieko
Department of Surgery, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa, 259-1193, Japan.
Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6.
BACKGROUND/AIMS: To investigate the recurrence patterns and interval from initial surgery in patients with curatively resected colorectal cancer followed for a minimum of 10 years.
We retrospectively reviewed 418 patients who had undergone curative resection for colon cancer (n = 246) or rectal cancer (n = 169). Follow-up periods ranged from 10 to 23 years. Main outcome measures were interval until recurrence, site of first recurrence, and influence of adjuvant chemotherapy.
26 (6%) had been lost to follow-up by 10 years and 143 (34%) had died. The most common site of recurrence was liver in colon cancer and locoregional in rectal cancer. The cumulative recurrence rate in colon cancer was 100% at 4 years. In rectal cancer, it was 89% at 5 years, 98% at 7 years and 100% at 10 years. The interval until recurrence was longer in rectal cancer (26.0 +/- 24.2 months) than in colon cancer (17.1 +/- 11.0 months) (p = 0.03). It was also longer in patients receiving than in those not receiving adjuvant chemotherapy (p < 0.01). The interval until lung metastasis was longer than that until liver metastasis in colon cancer (p = 0.04), and longer than that until locoregional recurrence in rectal cancer (p = 0.03). The interval until recurrence in the colon cancer was shorter for stage III than for stage II (p = 0.02).
Surveillance for recurrences, particularly for relapses in the liver and lung, should be performed for at least 4 years in colon cancer patients. Patients with rectal cancer should be followed for a longer period than those with colon cancer, focusing on locoregional, liver and lung recurrence. It is particularly noteworthy that adjuvant chemotherapy may prolong the interval until recurrence and the interval until lung metastasis is relatively longer.
背景/目的:调查接受根治性切除的结直肠癌患者至少随访10年的复发模式及首次手术后的复发间隔时间。
我们回顾性分析了418例行结肠癌(n = 246)或直肠癌(n = 169)根治性切除的患者。随访时间为10至23年。主要观察指标为复发间隔时间、首次复发部位及辅助化疗的影响。
到10年时,26例(6%)失访,143例(34%)死亡。结肠癌最常见的复发部位是肝脏,直肠癌是局部区域。结肠癌4年时累积复发率为100%。直肠癌5年时为89%,7年时为98%,10年时为100%。直肠癌的复发间隔时间(26.0±24.2个月)比结肠癌(17.1±11.0个月)长(p = 0.03)。接受辅助化疗患者的复发间隔时间也比未接受辅助化疗的患者长(p < 0.01)。结肠癌发生肺转移的间隔时间比发生肝转移的间隔时间长(p = 0.04),直肠癌发生肺转移的间隔时间比发生局部区域复发的间隔时间长(p = 0.03)。结肠癌Ⅲ期患者的复发间隔时间比Ⅱ期患者短(p = 0.02)。
结肠癌患者应至少进行4年的复发监测,尤其是肝脏和肺部的复发。直肠癌患者的随访时间应比结肠癌患者更长,重点关注局部区域、肝脏和肺部复发。特别值得注意的是,辅助化疗可能延长复发间隔时间,且发生肺转移的间隔时间相对较长。